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Abstract
Background: Multiple endocrine neoplasia type 1 (MEN1) is a hereditary cancer syndrome associated with several
endocrine as well as non-endocrine tumors and is caused by mutations in the MEN1 gene. Primary hyperparathyroidism
affects the majority of MEN1 individuals by age 50 years. Additionally, MEN1 mutations trigger familial isolated
hyperparathyroidism. We describe a seemingly unaffected 76-year-old female who presented to our Genetics
Clinic with a family history of primary hyperparathyroidism and the identification of a pathogenic MEN1 variant.
Case Presentation: The patient was a 76 year-old woman who appeared to be unaffected. She had a family
history of a known MEN1 pathogenic variant. Molecular testing for the known MEN1 mutation c.1A > G, as
well as, biochemical testing, MRI of the brain and abdomen were all performed using standard methods. Molecular
testing revealed our patient possessed the MEN1 pathogenic variant previously identified in her two offspring. Physical
exam revealed red facial papules with onset in her seventies, involving her cheeks, nose and upper lip. Formerly, she
was diagnosed with rosacea by a dermatologist and noted no improvement with treatment. Clinically, these lesions
appeared to be facial angiofibromas. Brain MRI was normal. However, an MRI of her abdomen revealed a 1.5 cm lesion
at the tail of the pancreas with normal adrenal glands. Glucagon was mildly elevated and pancreatic polypeptide was
nearly seven times the upper limit of the normal range. The patient underwent spleen sparing distal pancreatectomy
and subsequent pathology was consistent with a well-differentiated pancreatic neuroendocrine tumor (pNET).
Conclusions: Age-related penetrance and variable expressivity are well documented in families with MEN1. It
is thought that nearly all individuals with MEN1 manifest disease by age 40. We present a case of late-onset
MEN1 in the absence of the most common feature, primary hyperparathyroidism, but with the presence of a
pNET and cutaneous findings. This family expands the phenotype associated with the c.1A > G pathogenic
variant and highlights the importance of providing comprehensive assessment of MEN1 mutation carriers in
families that at first blush may appear to have isolated hyperparathyroidism.
Background
Multiple endocrine neoplasia 1 (MEN1) or Wermer’s
Syndrome is an autosomal dominant disorder caused by
germ line mutations in the MEN1 gene located in the
region 11q13.1 [1]. MEN1 is a tumor suppressor gene
that encodes for the protein, Menin. This 610 amino
acid protein is localized within the nucleus, has two
functional nuclear localization signals and represses
JunD mediated transcription. It is expressed in a variety
of tissues and is conserved across species from Drosophila
to Homo sapiens. Menin is proposed to act as a tumor
suppressor, as MEN1-associated tumors follow Knudson’s
“two-hit hypothesis” [2, 3]. MEN1 is characterized by the
presence of a combination of tumors of the parathyroid
glands, anterior pituitary, and Islet cells of the pancreas.
In addition, tumors of the adrenal cortex, facial angiofi-
bromas, carcinoid tumors, collagenous tumors, and lipo-
matous tumors have also been described. A clinical
diagnosis of MEN1 is made in cases where there is occur-
rence of two or more primary MEN1 tumor types, or
where there is one of the MEN1-associated tumors and a
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family member with a clinical diagnosis of MEN1. About
10–20% patients with familial MEN1 do not have a detect-
able pathogenic variant in the MEN1 gene [4]. The MEN1
phenotype is highly variable even within families and no
genotype-phenotype correlations have been made to date
[5]. The clinical presentation and age of diagnosis vary by
the type of tumor. Primary hyperparathyroidism is the
most common first presentation in patients with MEN1,
followed by Pancreatic Neuroendocrine Tumors (pNET)
and Pituitary tumors (PIT) [6]. In fact, primary hyperpara-
thyroidism is diagnosed in a majority of patients before
the diagnosis of MEN1. The age of diagnosis varies from
the first to the fifth decade, median age being 37 years for
patients with MEN1 pathogenic variants and 55 years for
patients without MEN1 pathogenic variants [6].
In this report we describe a case of MEN1 where diagno-
sis of hyperparathyroidism in family members prompted
the 76 years old asymptomatic proband to seek a genetics
referral. The report expands on the phenotype of this syn-
drome and also highlights the phenotypic variability associ-
ated with it.
Case Presentation
A 76 year- old female was referred to our genetics clinic
due to a family history of MEN1 in two children and a
familial pathogenic variant in MEN1. She did not have a
diagnosis of any of the “three P” tumors classic to MEN1 -
parathyroid, pituitary or pancreas. Her past medical his-
tory was significant for hypothyroidism and osteoporosis,
for which she was being appropriately treated with
levothyroxine and intermittent bisphosphate replacement.
She also had a history of lymphoma, which was treated
with Cyclophosphamide, Hydroxy doxorubicin, Vincris-
tine (Oncovin), and Prednisone (CHOP) regimen. Surgical
history was notable for a cholecystectomy. A complete
physical examination revealed no other abnormalities, ex-
cept for the presence of red papules on the cheeks, nose,
vermillion border of the upper lip and chin. The patient
reported that these papules had been present for the past
4–5 years. On closer examination by the geneticist, these
papules were diagnosed as facial angiofibromas (Fig. 1).
Her family history was significant for two daughters with
MEN1 diagnosed at 48 and 53 years of age and a son with
hypercalcemia and elevated parathyroid hormone levels
(Fig. 2). Following standard practice guidelines for first-
degree relatives of patients with MEN1, she was offered
targeted genetic testing for the known familial pathogenic
variant inMEN1. Screening for endocrine tumors was also
performed with MRIs of the head and abdomen (for pitu-
itary and pancreatic tumors). Plasma Ca++, parathyroid
hormone levels (PTH), prolactin and Insulin like Growth
Factor (IGF-1) levels, as well as fasting gastrointes-
tinal tract hormone profile, (that includes measure-
ment of gastrin, glucagon, vasointestinal polypeptide,
pancreatic polypeptide, chromogranin A, and insulin
with fasting glucose levels) were also performed.
Genetic testing was positive for the familial pathogenic
variant MEN1 c.1A > G, that results in the loss of the
translation initiation codon. The imaging revealed an
solitary enhancing, partially cystic pancreatic tail lesion
suggestive of a neuroendocrine tumor (Fig. 3) measuring
1.1 × 1.3 × 1.5 cm. Endoscopic ultrasound was then per-
formed which confirmed the lesion in the tail of the
pancreas and no other lesions were identified after thor-
ough inspection of the entire pancreas. Laboratory tests
revealed elevated pancreatic polypeptide of 2210 pg/mL,
while Chromogranin A was normal at 52 ng/mL. The
gastrointestinal hormone profile was significant only for
slightly elevated glucagon at 89 pg/mL. Given the isolated
pancreatic lesion, the patient was considered a candidate
for surgery. She underwent an uncomplicated laparo-
scopic spleen-preserving distal pancreatectomy and dis-
charged the next day. Pathology confirmed it to be a
1.4 × 1.0 cm well-differentiated neuroendocrine tumor,
positive for keratin, synaptophysin and chromogranin
stains. Regional lymph nodes were negative for metastatic
disease and the Ki67 index was less than 2%. Incidentally,
adenomatosis and an additional pNET measuring 2 mm
in size were identified.
Discussion and conclusions
The MEN1 c.1A > G pathogenic variant was first reported
in 2002 [7] in a family with a history of isolated hyperpara-
thyroid hormone levels and hypercalcemia, diagnosed
with familial isolated hyperparathyroidism (FIHP). The
pathogenic variant segregated with the disease in 3 out of
8 members tested across two generations, while one tested
Fig. 1 76 years old female proband with facial angiofibromas
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individual had no symptoms and was deemed at risk.
Additional literature reports [8] of this pathogenic variant
have been published with the affected patients having
variable symptoms like parathyroid and pancreatic islet
neoplasia with or without other tumors.
Other reports involving this start codon of MEN1, such
as c.2 T > A [9], also exhibit the intrafamilial phenotypic
variability associated with variation in this amino acid resi-
due, as different family members with the same patho-
genic variant are affected by different endocrine tumors.
In our case, the proband was asymptomatic on presenta-
tion, despite having two daughters that became symptom-
atic at the earlier ages of 44 and 48 years. One was
diagnosed with hyperparathyroidism and pNET while the
other had a diagnosis of hypercalcemia and gastrointes-
tinal symptoms. Both tested positive for the same MEN1
pathogenic variant, which prompted our asymptomatic
76 year-old patient to seek testing. Most patients with
MEN1 have shown biochemical manifestations by age
40–50 years [10–12]. Specifically pancreatic neuroen-
docrine tumors (pNET) are associated with an earlier
age of onset in patients with MEN1 mutations than
those without MEN1 mutations [10, 12–14]. In our
case, the patient did not exhibit any biochemical
symptoms of MEN1, in spite of being followed by
endocrinology for a history of hypothyroidism and
osteoporosis. The pancreatic tumor was found at
76 years of age only after an MRI of the abdomen
Fig. 2 Pedigree- the black arrow indicates the proband. The symbol * denoted individuals who underwent genetic testing for MEN1. The symbol +
denotes individuals who intend to get tested in the upcoming year
Fig. 3 Axial venous phase MRI showing an enhancing 1.5 cm cystic
mass consistent with pancreatic neuroendocrine tumor in the tail of
the pancreas (red arrow)
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was performed as standard protocol for screening MEN1
family members. This tumor could be correlated as being
non-functional given the increased chromogranin A
staining.
Regarding the patient’s co-existence of MEN1 and
lymphoma, there has been a prior case report [15] dem-
onstrating this, and indeed it is an interesting observa-
tion. Whilst no known association or mechanism exists
in the medical literature, to our knowledge this is only
the second case of MEN1 and lymphoma in the same
patient. This may be purely co-incidental however given
the lack of other cases.
Once our proband tested positive for the pathogenic
variant, she was encouraged to share her results with
other family members. Her son also tested positive for
the pathogenic variant and was found to have a pancre-
atic tumor on subsequent screening at age 57 years. This
highlights the value of medical genetics consultation in
patients with MEN1 so that family members at risk can
be regularly screened for the endocrine tumors.
This case report brings to attention the variable age of
diagnosis for MEN1, the phenotypic heterogeneity of
MEN1, even within the same family, and a proband that
was asymptomatic until age 76 years, barring facial angio-
fibromas. The report signifies the importance of medical
genetics consultation for diagnosis of MEN1, and, careful
screening for MEN1 associated tumors when a pathogenic
variant is identified.
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